

CAVELIER

ABOGADOS

www.cavelier.com
cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTA 8, COLOMBIA

1788 1788
Teléfono: (57-1) 347 3611
Telefax: (57-1) 211 8650
(57-1) 540 0860
Fax in U.S.A.: (1-305) 381 9660

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 02-117312- -00009-0000

Fecha: 2008-09-15 15:54:23 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 467 SOLICIPRORROGA Folios: 2

Trámite : 011
Evento : 379
Actuación : 467

Referencia : Expediente No. 02.117.312
Asunto : Solicitud de Patente **COMPUESTO PARA TRATAR
ENFERMEDAD DE ALZHEIMER**
Solicitante : **ELAN PHARMACEUTICALS, INC. AND PHARMACIA &
UPJOHN COMPANY**
Clase : A61K 031/013, C07C 233/078, C07C 237/000
Fecha de Solicitud : 30 de diciembre de 2002

1. Yo, Emilio FERRERO, como apoderado del solicitante, en el asunto antes identificado, atentamente solicito a Usted se sirva concederme un plazo de treinta (30) días, para atender el oficio No. **8168** notificado por fijación en lista del 20 de junio de 2008.

2. Presento con este memorial, el recibo expedido por el Fondo Especial de la Superintendencia de Industria y Comercio, en donde costa el pago hecho por valor de \$75.000 en conformidad con lo dispuesto en la resolución No. 44372 del 26 de diciembre de 2007.

Señora Jefe,

EMILIO FERRERO
T.P.A. No. 31.929

N. T. 24-10-2008
COLO-13562-841-001-5
ASG\MGMID-134333\WPC13562
No. M-2008-134333\ASG

28912

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 900176089-2

RECIBO OFICIAL DE CAJA : 08 - 69,266
FECHA : SEPTIEMBRE 1 DE 2008

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 02-117312- -00009-0000

Fecha: 2008-09-15 15:54:23 Dep. 2020 NUECREACIONI
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 467 SOLICIPRORROGA Folios: 2

**** CONSIGNACION ****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CAVELIER ABOGADOS	CONSIGNACION	BANCO DE BOGOTA	062754387	7438815	01/09/2008	50,610,000.00

**** CONCEPTO ****

CANT. RENTISTICO	CONCEPTO	TOTAL CONCEPTO
50005-01-08	PRORROGA DE TERMINOS	
31	PRORROGA DE TERMINOS	75,000.00
TOTAL :		75,000.00

SON: SESENTA Y CINCO MIL PESOS

RESPONSABLE : _____
RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

0010: 13562-871-001-5

CAVELIER

ABOGADOS

www.cavelier.com
cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTA 8, COLOMBIA

1790 179
Teléfono: (57-1) 347 3611
Telefax: (57-1) 211 8650
(57-1) 540 0860
Fax in U.S.A.: (1-305) 381 9660

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 02-117312- -00009-0000

Fecha: 2008-09-15 15:54:23 Dep: 2020 NUECREACIONE
Tra: 11 PATENTEIYII Eve: 379 FASENACIONALII
Act: 467 SOLICIPRORROGA Folios: 2

Trámite : 011
Evento : 379
Actuación : 467

Referencia : Expediente No. 02.117.312
Asunto : Solicitud de Patente **COMPUESTO PARA TRATAR ENFERMEDAD DE ALZHEIMER**
Solicitante : **ELAN PHARMACEUTICALS, INC. AND PHARMACIA & UPJOHN COMPANY**
Clase : A61K 031/013, C07C 233/078, C07C 237/000
Fecha de Solicitud : 30 de diciembre de 2002

1. Yo, Emilio FERRERO, como apoderado del solicitante, en el asunto antes identificado, atentamente solicito a Usted se sirva concederme un plazo de treinta (30) días, para atender el oficio No. **8168** notificado por fijación en lista del 20 de junio de 2008.

2. Presento con este memorial, el recibo expedido por el Fondo Especial de la Superintendencia de Industria y Comercio, en donde costa el pago hecho por valor de \$75.000 en conformidad con lo dispuesto en la resolución No. 44372 del 26 de diciembre de 2007.

Señora Jefe,

EMILIO FERRERO
T.P.A. No. 31.929

N. T. 24-10-2008
COLO-13562-841-001-5
ASG\MGM\ID-134333\WPC13562
No. M-2008-134333\ASG

CAVELIER

ABOGADOS

www.cavelier.com
cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTA 8, COLOMBIA

1791
Teléfono: (57-1) 347 3611
Telefax: (57-1) 211 8650
(57-1) 540 0860
Fax in U.S.A.: (1-305) 381 9660

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. _____ S. _____ D. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 02-117312- -00010-0000

Fecha: 2008-09-15 15:58:45 Dep. 2020 NUECRELACIONI
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 15

Trámite : 011
Evento : 379
Actuación : 444

Referencia : Expediente No. 02117312
Asunto : Solicitud de patente para: "COMPUESTOS
PARA TRATAR ENFERMEDAD DE ALZHEIMER"
Solicitante : ELAN PHARMACEUTICALS, INC. AND PHARMACIA
& UPJOHN COMPANY
Fecha de Solicitud : 30 de diciembre de 2002

1. Yo, Emilio FERRERO, obrando como apoderado del solicitante en el asunto antes identificado, me refiero al Oficio No. 8169 notificado por fijación en lista del 20 de junio de 2008, y atentamente presento junto con este escrito el siguiente documento:

- J.S. NG et al :TETRAHEDRON, VOL. 51 N° 23, 1995, págs. 6397-6410, XP0022200382.

2. Puesto que se han atendido a cabalidad las peticiones hechas por su Despacho sobre la presente solicitud de patente, atentamente solicito que se continúe su tramitación.

Señora Jefe,

EMILIO FERRERO

T.P.A. No. 31.929

COLO-13562-841-001-5
MGM\MGM\ID-134329\WPC13562
No. M-2008-134329\MGM

NIT 860.041.367-3

far sep 08
11/22/08



Pergamon

1292488
Tetrahedron Vol. 51, No. 23, pp. 6397-6410, 1995
Copyright © 1995 Elsevier Science Ltd
Printed in Great Britain. All rights reserved
0040-4020/95 \$9.50+0.00

0040-4020(95)00309-6

A Practical Synthesis of an HIV Protease Inhibitor Intermediate - Diastereoselective Epoxide Formation from Chiral α -Aminoaldehydes

John S. Ng*, Claire A. Przybyla, Chin Liu, Joe C. Yen, Frank W. Muellner and Cara L. Weyker

Chemical Sciences Department, Research and Development, Searle,
Skokie, Illinois 60077

Abstract: A practical and efficient synthesis of an HIV protease inhibitor intermediate has been developed based on the diastereoselective epoxide formation from a chiral α -aminoaldehyde and an *in situ* generated halomethylithium reagent.

INTRODUCTION


Human immunodeficiency virus type-1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS), encodes for a specific aspartyl proteinase (HIV protease)¹. Inhibition of this enzyme is regarded as a promising approach for the treatment of AIDS². Compounds incorporating hydroxyethylamine or hydroxyethylurea isosteres, as transition-state analogues, have been found to be highly potent inhibitors of HIV proteases.³ Due to the potential clinical importance of these compounds, many syntheses of intermediates leading to these types of compounds have been reported⁴; however, none of these methods would be readily amenable for the preparation of kilogram quantities of material. In this paper, we describe an efficient synthesis of a hydroxyethylurea intermediate used in the preparation of a HIV protease inhibitor, which is suitable for large scale production.

RESULTS AND DISCUSSION

The previously reported synthesis^{3a}, shown in Scheme I, was used to prepare initial


supplies of the hydroxyethylurea intermediate (6) required for the synthesis of a compound cited for development as a potential HIV protease inhibitor. The key protected epoxide (3) was prepared from a six-step synthesis starting from L-phenylalanine.⁵ The use of diazomethane, the low levels of diastereoselectivity in the sodium borohydride reduction (~50% d.e.) and low overall yield (~16%) made the scale up of this synthesis impractical.

Scheme I



In order to circumvent these problems, we developed an alternate synthesis of the hydroxyethylurea intermediate (6), which was based on a synthetic equivalent of epoxide (3), namely, chiral N, N, α -S-tris(phenylmethyl)-2S-oxiranemethanamine (9a), shown in Scheme II.

Scheme II



Starting from L-phenylalanine, the aldehyde (8) was synthesized in three steps by a modified Reetz procedure.⁶ First, N,N-bis(phenylmethyl)-L-phenylalanine, phenylmethyl ester was prepared from L-phenylalanine using benzyl bromide under aqueous conditions. The ester was then reduced with diisobutylaluminum hydride (DIBAL-H) in toluene. The substitution of DIBAL-H for lithium

1795 1795

aluminum hydride, as used by Reetz, provided a safer method for the reduction of the benzyl ester. The quench of the reaction mixture with aqueous acid gave a white solid from which the alcohol (7) was isolated after treatment with aqueous base and extraction with toluene. After one recrystallization, chemically (>99%) and optically pure (>99.5% ee) alcohol (7) was obtained in 65% yield. Alternatively, alcohol (7) could be obtained in one step in 88% yield by the benzylation of 2-amino-3-phenyl-1-propanol (L-phenylalaninol)⁷ using benzylbromide under aqueous conditions. The oxidation of alcohol (7) to aldehyde (8) was also modified from the Reetz procedure to allow for safe operation during scaleup. Instead of the standard Swern procedure⁸ using oxalyl chloride and DMSO in methylene chloride at low temperatures (-78 °C), the sulfur trioxide-pyridine/DMSO modification⁹, which could be conveniently performed at room temperature, was employed resulting in an excellent yield (100% crude product) of the desired analytically pure aldehyde (8). These modifications eliminated the need for kilogram scale chromatography and made the large scale operation much less hazardous to perform.

The key step in the synthesis shown in Scheme II, involved the reaction of chloromethylithium or bromomethylithium with the aldehyde (8) to form the required epoxide (9a). Previously, Reetz successfully prepared this epoxide from the reaction of the aldehyde with a sulfonium or sulfoxonium ylide¹⁰, however, our attempts to use this procedure resulted in significant racemization (10-80%). Although the reaction of halomethylithium reagents with aldehydes had been previously reported by Matteson¹¹, the addition of such species to chiral α -amino aldehydes to form α -aminoepoxides had not been investigated.¹² We found that the reaction of chloromethylithium or bromomethylithium with (8) did produce the *erythro* epoxide (9a) with good diastereoselectivity, similar to the results reported by Reetz which involved the addition of other nucleophiles to the same aldehyde.⁶ In this reaction, the halomethylithium reagent was generated by the addition of n-butyllithium to a cold (-78 to -30 °C) THF solution of either chloriodomethane, bromochloromethane or dibromomethane in the presence of aldehyde (8). It is necessary to have the aldehyde present because of the instability of the halomethylithium reagent. Also, several additions of the dihalomethane and n-butyllithium reagents are required to maximize the conversion of aldehyde to the epoxide. Chlorohydrin products could be isolated from the reaction of aldehyde (8) with chloromethylithium if the reaction mixture was quenched at low temperatures.¹³ Epoxides (9a and 9b) were produced in an 85:15 ratio from the reaction of aldehyde (8) with chloromethylithium after warming to room temperature or from the reaction of the aldehyde with bromomethylithium at colder temperatures.¹⁴ The *erythro* epoxide (9a) could be isolated by chromatography as an oil in a 65% yield, however, it was found the crude product could be used directly without purification.¹⁵


The crude epoxide mixture was treated with isobutylamine in isopropanol at 80 °C for 1.5

17961796

hours to give the crude diastereomeric amine mixture (10a+10b) in a good yield (95% by quantitative HPLC analysis). Reaction of the crude amine with *t*-butyl isocyanate in methylene chloride, THF or ethyl acetate at room temperature for 10-30 minutes provided a diastereomeric mixture of ureas in 94% yield by quantitative HPLC analysis. The desired diastereomer (11) was purified by one recrystallization of the crude product from ethyl acetate/heptane in an overall yield of 52% from (7). Hydrogenation using Pearlman's catalyst (20% palladium hydroxide on carbon) in methanol resulted in a quantitative yield of the amino hydroxyethylurea intermediate (6), which was shown by NMR and HPLC analyses to be identical to the compound previously prepared according to the route depicted in Scheme I. This method was used to prepare intermediate (6) which was then used successfully to synthesize potent HIV protease inhibitors containing the hydroxyethylurea moiety according to a recently published procedure.^{3a}

In order to ensure that the HIV protease inhibitors prepared by this method were of high enantiomeric purity, we developed four HPLC methods to analyze for the enantiomeric excess of various key intermediates. Enantiomers of intermediate (7) were resolved on a Astec Cyclobond I SP HPLC column and the enantiomers of intermediates (8) and (9) were separated on a Regis (S,S)-Whelk-O 1 HPLC column. Intermediate (10a) was converted to the diaminoalcohol (12) by debenzoylation as shown in Scheme III and the product was analyzed using a Daicel Chiral Crown Pak CR(+) column. In all cases, the intermediates from the synthesis described were determined to be of high optical purity (>99.5% ee).

Scheme III



The synthesis described here was successfully scaled up to the multikilogram level. Several advantages of this route over other syntheses for the large scale preparation of compounds

1797 1797

containing the hydroxyethylamine moiety are as follows: (1) the elimination of the use of extremely hazardous reagents, such as diazomethane, (2) no purifications by chromatography are required (3) the use of inexpensive and readily available starting materials and (4) the route is short and efficient.

CONCLUSION

Diastereoselective epoxide formation, from *N,N*-dibenzyl protected chiral α -amino-aldehydes and *in situ* generated halomethylolithium reagents, has been demonstrated to be an effective method for the large scale production of a hydroxyethylurea intermediate used for the preparation HIV protease inhibitors.

EXPERIMENTAL SECTION

Electron impact and chemical ionization mass spectra were obtained using a Finnigan-MAT 8430 mass spectrometer, a Finnigan-MAT SS300 data system, and a desorption probe at a source temperature of 170 °C. Ammonia was used as the CI reagent gas. The proton and carbon-13 NMR spectra were recorded on a GE QE-300 or a Varian VXR400 spectrometer with $\text{Me}_4\text{Si-d}_{12}$ as an internal standard. Infrared (IR) spectra were recorded using a Perkin Elmer Model 681 spectrophotometer and CHCl_3 solutions. Elemental analyses were determined with a Control Equipment Corporation 240XA analyzer. Differential scanning calorimetry (DSC) thermograms were obtained using a DuPont Model 9900 thermal analysis system. Solvents and reagents were obtained from commercial sources and were not further purified unless specified. Gas chromatography was performed on a Hewlett Packard 5890 gas chromatograph equipped with a methyl silicone column (15m x 0.25 x 0.25 μm film thickness). Optical rotations were measured on a Perkin Elmer 241 polarimeter with a path length of 1 dm. Concentrations were given in g/mL. Purchased raw materials were of reagent grade and used without purification. Tetrahydrofuran was purified by distillation from sodium benzophenone ketyl. Merck Silica Gel 60 was used in the chromatographic purification of all specified products.

β S-2-[Bis(phenylmethyl)amino]benzenepropanol (7)

METHOD 1

Step 1: Benzylation of L-Phenylalanine

A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 mL) was heated to 97 °C. Benzyl bromide

17918 17918

(108.5 mL, 0.605 mol) was then slowly added. The mixture was stirred at 97 °C for 30 minutes. The solution was cooled to room temperature and extracted with toluene (2 x 250 mL). The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and concentrated to an oil. Analytical tlc (10% ethyl acetate/hexane, silica gel) showed the major component (R_f =0.32) to be the desired tribenzylated compound, N, N-bis(phenylmethyl)-L-phenylalanine, phenylmethyl ester. The product can be purified by column chromatography (silica gel, 15% ethyl acetate/hexanes), however, the crude product was usually used directly in the next step without further purification. ^1H NMR spectrum was in agreement with published literature.⁶ ^1H NMR (CDCl_3) δ 3.00 and 3.14 (ABX-system, 2H, J_{AB} =14.1 Hz, J_{AX} =7.3 Hz and J_{BX} = 5.9 Hz), 3.54 and 3.92 (AB-System, 4 H, J_{AB} =13.9 Hz), 3.71 (t, 1H, J =7.6 Hz), 5.11 and 5.23 (AB-System, 2H, J_{AB} =12.3 Hz), and 7.18 (m, 20 H); EIMS: m/z 434 (M-1).

Step 2: β S-2-[Bis(phenylmethyl)amino]benzenepropanol (7) from the diisobutylaluminum hydride (DIBAL-H) reduction of N, N-bis(phenylmethyl)-L-phenylalanine, phenylmethyl ester: N, N-bis(phenylmethyl)-L-phenylalanine, phenylmethyl ester (0.302 mol), from Step 1 was dissolved in toluene (750 mL) and cooled to -55 °C. A 1.5 M solution of DIBAL-H in toluene (443.9 mL, 0.666 mol) was added at a rate to maintain the temperature between -55 to -50 °C. The mixture was stirred for 20 minutes and then quenched at -55 °C by the slow addition of methanol (37 mL). The cold solution was then poured into cold (5 °C) 1.5 N HCl solution (1.8 L). The precipitated solid was filtered off and washed with toluene. The solid was suspended in a mixture of toluene (400 mL) and water (100 mL), cooled to 5 °C and treated with 2.5 N NaOH (186 mL). The mixture was stirred at room temperature until the solid dissolved. The toluene layer was separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 mL (89 g). Ethyl acetate (25 mL) and hexane (75 mL) were added to the residue upon which the desired alcohol precipitated. The solid was filtered and washed with 50 mL hexane to give 34.9 g of product as the first crop. A second crop of product (5.6 g) was isolated by refiltering the mother liquor. Recrystallization of the two combined crops from ethyl acetate (20 mL) and hexane (30 mL) gave 40 g of β S-2-[Bis(phenylmethyl)amino]benzenepropanol (7), 40% yield from L-phenylalanine. An additional 7 g (7%) of product was obtained by recrystallization of the concentrated mother liquor. TLC (10% ethyl acetate/hexane, silica gel) : R_f = 0.23; mp 71.5-73.0 °C; ^1H NMR (CDCl_3) δ 2.44 (m, 1H), 3.09 (m, 2H), 3.33 (m, 1H), 3.48 and 3.92 (AB-System, 4H, J_{AB} = 13.3 Hz), 3.52 (m, 1H) and 7.23 (m, 15H); $[\alpha]_D^{25}$ +42.4 (c 1.45, CH_2Cl_2); DSC 77.67°C; Anal. Calcd. for $\text{C}_{23}\text{H}_{25}\text{ON}$: C, 83.34; H, 7.60; N, 4.23. Found: C, 83.43; H, 7.59; N, 4.22. HPLC analysis on chiral stationary phase, Astec Cyclobond I SP column (250 x 4.6 mm I.D.), mobile phase:

methanol/ triethyl ammonium acetate buffer pH 4.2 (58:42, v/v), flow-rate of 0.5 ml/min, detection with UV detector at 230nm and a temperature of 0 °C. Retention time of (7): 11.25 min., retention time of enantiomer of (7): 12.5 min.

METHOD 2

Preparation of β S-2-[bis(phenylmethyl)amino]benzenepropanol (7) from the N, N-dibenzylation of 2-amino-3-phenyl-1-propanol (L-phenylalaninol): L-Phenylalaninol (176.6 g, 1.168 mol) was added to a solution of potassium carbonate (484.6 g, 3.506 mol) in 710 mL of water. The mixture was heated to 65 °C. A solution of benzyl bromide (400 g, 2.339 mol) in ethanol (305 mL) was added at a rate that maintained the temperature between 60-68 °C. The biphasic solution was stirred at 65 °C for 55 min and then allowed to cool to 10 °C with vigorous stirring. The oily product solidified into small granules. The mixture was diluted with 2.0 L of tap water and stirred for 5 minutes to dissolve the inorganic salts. The product was isolated by filtration and washed with water until the pH was 7. The crude product was air-dried overnight to give a white solid (407 g) which was recrystallized from 1.1 L of ethyl acetate/heptane (1:10 by volume). The product was isolated by filtration (at -8 °C), washed with 1.6 L of cold (-10 °C) ethyl acetate/heptane (1:10 by volume) and air-dried to give 339 g (88% yield) of β S-2-[Bis(phenylmethyl)amino]-benzenepropanol (7), mp 71.5-73.0 °C. This compound was identical to that prepared by method 1.

α S-[Bis(phenylmethyl)amino]benzenepropanaldehyde (8)

β S-2-[Bis(phenylmethyl)amino]benzenepropanol (7) (200 g, 0.604 mol) was dissolved in triethylamine (300 mL, 2.15 mol). The mixture was cooled to 12 °C and a solution of sulfur trioxide/pyridine complex (380 g, 2.39 mol) in DMSO (1.6 L) was added at a rate to maintain the temperature between 8-17 °C (addition time - 1.0 h). The solution was stirred at ambient temperature for 1.5 h at which time the reaction was complete by TLC analysis (33% ethyl acetate/hexane, silica gel). The reaction mixture was cooled in an ice/water bath and quenched by the addition of 1.6 L of cold water (10-15 °C) over 45 minutes. The dimethyl sulfide by-product was removed by sparging the quenched reaction mixture with nitrogen and scrubbing the off gas with 5% bleach solution. The product solution was extracted with ethyl acetate (2.0 L), washed with 5% citric acid (2.0 L), brine (2.2 L), dried over MgSO_4 (280 g) and filtered. The solvent was removed on a rotary evaporator at 35-40 °C and then dried under vacuum to give 198.8 g of α S-[Bis-(phenylmethyl)amino]-benzenepropanaldehyde (8) as a pale yellow oil (99.9%). The crude product was used directly in the next step without purification. The analytical data of the compound were consistent with the published literature⁶. $[\alpha]_{\text{D}}^{25} = -92.9^\circ$ (c 1.87, CH_2Cl_2); ^1H

1800 1801

NMR (100 MHz, CDCl_3) δ 2.94 and 3.15 (ABX-System, 2H, $J_{AB} = 13.9$ Hz, $J_{AX} = 7.3$ Hz and $J_{BX} = 6.2$ Hz), 3.56 (t, 1H, 7.1 Hz), 3.69 and 3.82 (AB-System, 4H, $J_{AB} = 13.7$ Hz), 7.25 (m, 15 H) and 9.72 (s, 1H); HRMS calcd for (M+1) $\text{C}_{23}\text{H}_{24}\text{NO}$ 330.450, found: 330.1836. Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{ON}$: C, 83.86; H, 7.04; N, 4.25. Found: C, 83.64; H, 7.42; N, 4.19. HPLC on chiral stationary phase: Regis (S,S)-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector at 210nm. Retention time of (8): 8.75 min., retention time of enantiomer of (8): 10.62 min.

**N,N, α S-Tris(phenylmethyl)-2S-oxiranemethanamine (9a) and
N,N, α S-Tris(phenylmethyl)-2R-oxiranemethanamine (9b)**

A solution of α S-[Bis-(phenylmethyl)amino]benzenepropanaldehyde (8) (191.7 g, 0.58 mol) and chloriodomethane (56.4 mL, 0.77 mol) in tetrahydrofuran (1.8 L) was cooled to -30 to -35 °C in a stainless steel reactor. A solution of n-butyllithium in hexane (1.6 M, 365 mL, 0.58 mol) was then added at a rate that maintained the temperature below -25 °C. After the addition, the mixture was stirred at -30 to -35 °C for 10 minutes. Additional chloriodomethane and n-butyllithium were added many times in small portions in the same manner to maximize the conversion of the aldehyde to the epoxide. The specific additions were as follows: 2 additions of 17 ml (0.22 mol) of chloriodomethane and 110 ml (0.18 mol) of n-butyllithium; 6 additions of 8.5 ml (0.11mol) of chloriodomethane and 55ml (0.09 mol) n-butyllithium; and one addition of 8.5 ml (0.11 mol) of chloriodomethane and 37 ml (0.06 mol) of n-butyllithium. After the final addition of the reagents, the mixture was stirred at -30 to -35 °C for 10 minutes and then the external cooling was stopped. The mixture warmed to ambient temperature over 4 hours. TLC analysis of the reaction mixture (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was complete. The reaction mixture was cooled to 10 °C and quenched by the addition of 1.4 L of 16% ammonium chloride solution (prepared by dissolving 232 g of ammonium chloride in 1.2 L of water), at a rate which kept the temperature below 23 °C. After the addition was complete, the mixture was stirred for 10 minutes and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 500 mL). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined solution was dried over magnesium sulfate (220 g), filtered and concentrated on a rotary evaporator at 65 °C. The oily residue was dried at 70 °C *in vacuo* (0.8 bar) for 1 h to give 222.8 g (>100% yield) of crude product. Quantitative HPLC analysis of the crude product indicated ~ 85 % yield of the mixture of the two epoxide diastereomers (9a) and (9b). Due to the relative instability of the product on silica gel, the crude product was used directly in the next step without purification. The diastereomeric ratio of the crude mixture was determined

by proton NMR to be: (9a)/(9b): 86:14. The minor and major epoxide diastereomers were also characterized in this mixture by tlc analysis (silica gel, 10% ethyl acetate/hexane), $R_f = 0.29$ & 0.32, respectively. An analytical sample of each of the diastereomers was obtained by purification on silica-gel chromatography (3% ethyl acetate/hexane) and characterized as follows:

N,N, α S-Tris(phenylmethyl)-2S-oxiranemethanamine (9a)

^1H NMR (400 MHz, CDCl_3) δ 2.49 and 2.51 (AB-System, 1H, $J_{AB} = 2.82$), 2.76 and 2.77 (AB-System, 1H, $J_{AB} = 4.03$), 2.83 (m, 2H), 2.99 & 3.03 (AB-System, 1H, $J_{AB} = 10.1$ Hz), 3.15 (m, 1H), 3.73 & 3.84 (AB-System, 4H, $J_{AB} = 14.00$), 7.21 (m, 15H); ^{13}C NMR (100 MHz, CDCl_3) δ 139.6, 129.5, 128.4, 128.1, 128.1, 126.8, 126.0, 60.3, 54.2, 52.1, 46.0, 33.8; HRMS calcd for $\text{C}_{24}\text{H}_{26}\text{NO}$ ($M+1$) 344.477, found 344.2003.

N, N, α S-Tris(phenylmethyl)-2R-oxiranemethanamine (9b)

^1H NMR (300 MHz, CDCl_3) δ 2.20 (m, 1H), 2.59 (m, 1H), 2.75 (m, 2H), 2.97 (m, 1H), 3.14 (m, 1H), 3.85 (AB-System, 4H), 7.25 (m, 15H). HPLC analysis on chiral stationary phase: Regis (S,S)-Wheik-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector at 210 nm. Retention time of (9a): 9.38 min., retention time of enantiomer (9b): 13.75 min.

β S-[Bis(phenylmethyl)amino]- α R-[(2-methylpropyl)amino]methyl]-benzenepropanol (10a)

To a solution of the crude epoxides 9a and 9b (388.5 g, 1.13 mol) in isopropanol (2.7 L) was added isobutylamine (1.7 kgm, 23.1 mol). The temperature increased from 25 °C to 30 °C during the addition. The solution was heated to 82 °C and stirred at this temperature for 1.5 h. The warm solution was concentrated under reduced pressure at 65 °C. The concentrate was transferred to a 3-L flask and dried *in vacuo* (0.8 mm Hg) for 16 h to give 450 g of a mixture of the desired β S-[Bis(phenylmethyl)amino]- α R-[(2-methylpropyl)amino]methyl]-benzenepropanol (10a) and undesired SS diastereomer 10b as a crude oil. The crude product was used directly in the next step without purification. An analytical sample of the desired major diastereomeric product was obtained by purifying a small sample of crude product by silica gel chromatography (40% ethyl acetate/hexane). TLC analysis (silica gel, 40% ethyl acetate/hexane) $R_f = 0.28$, HPLC analysis: Altex ultrasphere ODS column, 25% triethylamine-/phosphate buffer pH 3/acetonitrile, flow rate 1 mL/min, UV detector; retention time 7.49 min. ^1H NMR (400 MHz, CDCl_3) δ 0.88 (d, 6H, $J = 6.64$), 1.68 (m, 1H), 2.33 (dd, 1H, $J = 11.6, 6.76$), 2.41 (dd, 1H, $J = 11.6, 6.96$), 2.47 (dd, 1H, $J = 12.0, 9.26$), 2.77 (dd, 1H, $J = 12.0, 3.32$), 2.86 (m, 1H), 2.98 (dd, 1H, $J = 14.2$,

5.04), 3.05 (dd, 1H, $J = 14.2, 7.95$), 3.62 (d, 2H, $J = 13.8$), 3.69 (d, 2H, $J = 13.8$), 3.92 (m, 1H), 7.09-7.34 (complex, 15H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.5, 139.9, 129.6, 128.8, 128.8, 128.2, 128.1, 128.0, 128.1, 126.8, 125.7, 68.7, 62.3, 57.3, 54.6, 53.1, 32.6, 28.2, 20.5, 20.5; HRMS calcd for $\text{C}_{28}\text{H}_{37}\text{N}_2\text{O}$ ($M + 1$) 417.616, found 417.2887.

N-[3S-[Bis(phenylmethyl)amino]-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea (11)

A solution of the crude amines 10a and 10b (446.0 g, 1.1 mol) in tetrahydrofuran (6 L)¹⁶ was cooled to 8 °C. *Tert*-butyl isocyanate (109.5 g, 1.1 mol) was then added to the solution of the amine from an addition funnel at a rate which maintained the temperature between 10-12 °C. After the addition was complete, the external cooling was stopped and the reaction warmed to 18 °C over 30 min. The solution was concentrated under vacuum at 50 °C. The residue was dissolved in ethyl acetate (3 L), washed with 5% aq citric acid solution (1 x 1.2 L), water (2 x 500 mL), brine (1 x 400 mL), dried over magnesium sulfate (200 g) and filtered. The volume of solution was reduced to 671 mL over 2 h on a rotary evaporator at 50 °C. The concentrate was diluted with 1.6 L of hexane and cooled to 12 °C to crystallize out the desired urea diastereomer. The product was isolated by filtration, washed with 10% ethyl acetate/hexane (1 x 500 mL), hexane (1 x 200 mL) and then dried *in vacuo* (2 mm) at 50 °C for 1 hour to give 248 g of N-[3S-[Bis(phenylmethyl)amino]-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)-urea (11) as an off white solid. The mother liquor and washes were combined and concentrated on a rotary evaporator to give 270 g of a brown oil. This material was dissolved in ethyl acetate (140 mL) at 50 °C and diluted with hexane (280 mL) and seeded with crystals of the first crop product (20 mg). The mixture was cooled in an ice bath and stirred for 1 h. The solid was isolated by filtration, washed with 10% ethyl acetate/hexane (1 x 200 mL) and dried *in vacuo* (2 mm) at 50 °C for 1 h to give 55.7 g of 11 as the second crop (overall yield of 11 from 7: 49%). Analytical data for the first crop of 11: Mp 126 °C; $[\alpha]_{\text{D}}^{25} = -59.0^\circ$ ($c = 1.0$, CH_2Cl_2), TLC (silica gel, 25% ethyl acetate/hexane) $R_f = 0.31$, ^1H NMR (400 MHz, CDCl_3) δ 0.89 (d, 3H, $J = 6.60$), 0.92 (d, 3H, $J = 6.59$), 1.31 (s, 9H), 1.83 (m, 1H), 2.78-2.90 (complex, 3H), 3.00-3.06 (complex, 3H), 3.48 (dd, 1H, $J = 14.8, 9.89$), 3.65 (d, 2H, $J = 14.1$), 3.70 (d, 2H, $J = 14.1$), 3.97 (m, 1H), 4.48 (s, 1H), 4.75 (d, 1H, $J = 3.34$), 7.10-7.30 (complex, 15H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.7, 141.5, 139.9, 129.7, 128.7, 128.2, 126.9, 125.7, 71.6, 62.5, 56.6, 54.7, 53.9, 50.9, 32.1, 29.5, 28.1, 20.5, 20.3.

An analytical sample of the undesired minor diastereomer, N-[3S-[bis(phenylmethyl)amino]-2S-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethylethyl)-N-(2-methylpropyl)urea

1803-1803

was isolated by silica-gel chromatography (10-15% ethyl acetate/hexane) in an earlier experiment and characterized. ^1H NMR (400 MHz, CDCl_3) δ 0.77 (d, 6H, $J = 6.59$), 1.26 (s, 9H), 1.69 (m, 1H), 2.68-2.79 (complex, 3H), 2.82-2.91 (complex, 2H), 3.16 (dd, 1H, $J = 13.7, 5.67$), 3.32 (dd, 1H, $J = 15.3, 8.34$), 3.41 (d, 2H, $J = 13.2$), 3.64 (m, 1H), 3.99 (d, 2H, $J = 13.2$), 5.10 (br s, 1H), 5.26 (br s, 1H), 7.20-7.35 (complex, 15H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.1, 139.9, 138.9, 129.2, 129.1, 128.7, 128.6, 128.4, 127.2, 126.3, 71.7, 61.7, 55.8, 54.2, 53.8, 50.2, 32.1, 29.4, 27.6, 20.2, 20.0; HRMS calcd for $\text{C}_{33}\text{H}_{46}\text{N}_3\text{O}_2$ ($M+1$) 516.749, found 516.3591.

N-(3S-Amino)-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methyl-propyl)urea (6)

N-[3S-[Bis(phenylmethyl)amino]-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea 11 (125.77 g, 0.244 mol) was dissolved in ethanol (1.5 L) and 20% palladium hydroxide on carbon (18.87 g) was added to the solution under nitrogen. The mixture was stirred at ambient temp under a hydrogen atmosphere at 60 psi for 8 h. The catalyst was removed by filtration and the filtrate was concentrated to give 85 g of N-(3S-Amino)-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methyl-propyl)urea (6) as a colorless oil. The proton and carbon NMR spectra of this material were in agreement with the spectra of a reference standard prepared from the chloromethylketone in Scheme I. ^1H NMR (400 MHz, CD_3OD) δ 0.87 (d, 3H, $J = 6.61$), 0.88 (d, 3H, $J = 6.61$), 1.31 (s, 9H), 1.93 (m, 1H), 2.59 (dd, 1H, $J = 13.6, 8.79$), 2.95-3.06 (complex, 3H), 3.15 (dd, 1H, $J = 14.3, 7.99$), 3.30-3.42 (complex, 2H), 3.67 (m, 1H), 7.20-7.33 (complex, 5H); ^{13}C NMR (100 MHz, CD_3OD) δ 161.0, 139.0, 130.3, 129.6, 127.5, 74.8, 57.2, 56.2, 52.1, 39.2, 29.7, 28.5, 20.5, 20.3.

ACKNOWLEDGEMENT

We like to gratefully acknowledge Dr. Hugo Gorissen, Mr. Jean Pierre and Mr. Luc Antoine of Searle European Development Center for their help in the large scale synthesis.

REFERENCES AND FOOTNOTES

1. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K.J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumister, K.; Ivanoff, L.; Petteway, Jr. S. R.; Pearson, M.L.; Lautenberger, J. A.; Papas, T. S.; Ghrayeb, J.; Chang, N.T.; Gallo, R.

1804

- C.; Wong-Stahl, F. Complete nucleotide Sequence of the AIDS virus, HTLV-III. *Nature*, 1985, 313, 277.
2. Huff, J. R., *J. Med. Chem.*, 1991, 34, 2305 and references cited therein.
 3. (a) Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M.L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R.A. *J. Med. Chem.*, 1993, 346, 288; (b) Krohn, A.; Redshaw, S.; Ritchie, J. C.; Graves, B. J.; Hatada, M. H. *J. Med. Chem.*, 1991, 34, 3340; (c) Roberts, N. A.; Martin, J. A.; Kinnchington, D.; Broadhurst, A. V.; Craig, C.; Duncan, I.B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Redshaw, S.; Ritchie, A.J.; Taylor, D. L.; Thomas, G. J.; Machlin, P. J. *Science*, 1990, 248, 358.
 4. (a) Albeck, A.; Persky, R. *Tetrahedron*, 1994, 50, 6333. (b) Barluenga, J.; Baragana, B.; Alonso, A.; Concellon, J.M. *J. Chem. Soc., Chem. Commun.*, 1994, 969. (c) Barrish, J.C.; Gordon, E.; Alam, M.; Lin, P.F.; Bisacchi, G.S.; Chen, P.; Cheng, P.T.; Fritz, A.; Greytok, J.A.; Hermsmeier, M.A.; Humphreys, W.G.; Lis, K.A.; Marella, M.A.; Merchant, Z.; Mitt, T.; Morrison, R.A.; Obermeier, M.T.; Pluscec, J.; Skoog, M.; Slusarchyk, W.A.; Spergel, S.H.; Stevenson, J.M.; Sun, C.; Sundeen, J.E.; Taunk, P.; Tino, J.A.; Warrack, B.A.; Colonno, R.J.; Zahler, R. *J. Am. Chem. Soc.* 1994, 37, 1758. (d) Gurjar, M.K.; Devi, N.R. *Tetrahedron: Asymmetry*, 1994, 5, 755. (e) Parkes, K.E.B.; Bushnell, D.J.; Crackett, P.H.; Dunsdon, S.J.; Freeman, A.C.; Gunn, M.P.; Hopkins, R.A.; Lambert, R.W.; Martin, J.A.; Merrett, J.H.; Redshaw, S.; Spurden, W.C.; Thomas, G.J. *J. Org. Chem.*, 1994, 59, 3656. (f) Pegorier, L.; Petit, Y.; Larcheveque, M. *J. Chem. Soc., Chem. Commun.*, 1994, 633. (g) Sasai, H.; Kim, W.S.; Suzuki, T.; Shibasaki, M.; Mitsuda, M.; Hasegawa, J.; Ohashi, T. *Tetrahedron Lett.*, 1994, 35, 6123. (h) Shum, W.P.; Chen, J.; Cannarsa, M.J.; *Chirality*, 1994, 6, 681. (i) Bennett, F.; Girijavallabhan, V.M.; Patel, N. *J. Chem. Soc., Chem Commun.*, 1993, 737. (j) Thompson, W.J.; Ghosh, A.K.; Holloway, M.K.; Lee, H.Y.; Munson, P.M.; Schwering, J.E.; Wai, J.; Darke, P.L.; Zugay, J.; Emini, E.A.; Schleif, W.A.; Huff, J.R.; Anderson, P.S. *J. Am. Chem. Soc.*, 1993, 115, 801. (k) Askin, D.; Wallace, M.A.; Vacca, J.P.; Reamer, R.A.; Volante, R.P.; Shinkai, I. *J. Org. Chem.*, 1992, 2771. (l) Ghosh, A.K.; McKee, S.P.; Lee, H.Y.; Thompson, W.J. *J. Chem. Soc., Chem Commun.*, 1992, 273. (m) Luly, J.R.; Dellaria, J.F.; Plattner, J.J.; Soderquist, J.L.; Yi, N. *J. Org. Chem.*, 1987, 52, 1487. (n) Evans, B.E.; Rittle, K.E.; Homnick, C.F.; Springer, J.P.; Hirshfield, J.; Veber, D.F. *J. Org. Chem.*, 1985, 50, 4615.

5. The chloromethylketone intermediate (1) can be purchased from BACHEM at \$1200-1600/kg on a contracted basis, however, this high cost could make the use of this starting material on large scale synthesis cost-prohibitive.
6. (a) Reetz, M.T., Drewes, M. W and Schmitz, A., *Angew Chem.*, 1987, 99, 1186; *Angew Chem. Int. Ed. Engl.*, 1987, 26, 1141; (b) Drewes, M. W., PhD Thesis, der Philipps-Universitat Marburg/Lahn, 1988.
7. L-Phenylalaninol can be purchased from many bulk suppliers such as Newport Synthesis Ireland Ltd, Nutrasweet Company (US) or Degussa (Germany) in multikilogram quantities.
8. Swern, D., *J. Org. Chem.*, 1978, 43, 2480.
9. Parikh, J., Doering, W., *J. Am. Chem. Soc.*, 1967, 89, 5505.
10. Reetz, M.T., Drewes, M. W., Harms and W. Reif *Tetrahedron Lett*, 1988, 29, 3295.
11. Matteson, D.S., Michnick, T.J., *SYNLETT*, 1991, 631 and the references therein.
12. The first preparation of chiral functionalised ketones and epoxides was reported during the preparation of this manuscript. Barleunga, J.; Baragana, B.; Alonso, A.; Concellon, J. . *J. Chem. Soc., Chem. Comm.*, 1994, 969.
13. Structures were confirmed by NMR analysis of reaction products after purification by chromatography.
14. The diastereomeric ratio was determined by both proton NMR and HPLC analyses.
15. The yields of the mixture of epoxides (9a + 9b) in the crude reaction mixture were assayed to be approximately 85 % by quantitative HPLC analysis. The yields of the isolated epoxides might be lower due decompositon during chromatography.
16. Methylene chloride or ethyl acetate can be substituted for tetrahydrofuran.

(Received in USA 13 February 1995; revised 17 April 1995; accepted 18 April 1995)